Country Access Report
Medical Access in United States
Esketamine nasal spray is the clearest nationally reimbursable psychiatric access pathway, with SPRAVATO administered under a REMS in certified healthcare settings. Off-label racemic ketamine is widely available in private clinics, but insurance coverage is inconsistent and compounded products carry additional regulatory and safety caveats. Psilocybin, MDMA, LSD, DMT, 5-MeO-DMT, ibogaine and mescaline still lack FDA approval, so access is mainly through clinical trials, state-specific programmes, or self-pay service models where lawful.
- Access Level
- Mixed: esketamine/ketamine access, trials, and state-specific programmes
- Compounds Covered
- 0
- Active Trials
- 163
How To Use This Guide
Read the access level as a starting point, then check the compound notes below. The practical question is whether a patient can move through a real pathway today, or whether access still depends on a trial, exception route, private-care model, or future reimbursement decision.
Available Today
Look for approved use, named specialist settings, eligibility rules, and whether care is routine or exceptional.
Research Or Exception
Separate clinical trials, special access, compassionate use, and unlicensed-medicine routes from routine medical availability.
Payment And Delivery
Check who pays, where care can happen, and whether trained teams, product supply, and site governance are in place.
Access By Compound
These notes separate what is available today from research, exceptional-access, private-care, and payment routes. When the guide has not verified a pathway, the compound stays marked as incomplete rather than treated as unavailable.
Blossom has not reviewed compound-specific access information for this country yet.
Sources and Review
Last updated 15 May 2026. Source links come from the medical access guide.